HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here

HDFC Mutual Fund has increased its stake in Glenmark Pharmaceuticals, breaching the 5 percent ownership threshold, as per the company's regulatory filing on June 18, 2025. The move comes even as Glenmark disclosed recent regulatory scrutiny of its U.S. manufacturing facility by the United States Food and Drug Administration (USFDA).
According to the filing, HDFC Mutual Fund purchased an additional 3.57 lakh equity shares of Glenmark Pharma, raising its holding by 0.13 percent. Prior to the transaction, the fund house held 1.39 crore shares, or 4.94 percent of the company. Post acquisition, its total shareholding stands at 1.43 crore shares, which translates to a 5.07 percent stake in the pharmaceutical major.
The stake increase is seen as a mark of confidence in the company's fundamentals and long-term growth potential, especially amid recent regulatory developments. As per the March 2025 shareholding pattern, Glenmark's promoters continue to hold a dominant 46.65 percent stake in the company.
In parallel with the stake hike, Glenmark Pharmaceuticals also updated the stock exchanges about a recent Good Manufacturing Practice (GMP) inspection conducted by the USFDA at its Monroe, North Carolina facility in the U.S. The inspection, which spanned from June 9 to June 17, 2025, culminated in the issuance of a Form 483 with five observations.
The company was quick to clarify that the observations were procedural in nature and did not pertain to data integrity—an issue that often raises red flags in the pharmaceutical industry. In its exchange communication, Glenmark stated, 'The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.'
A Form 483 is typically issued when the FDA investigator identifies possible violations of the Food, Drug, and Cosmetic (FD&C) Act, but the absence of critical concerns such as data falsification is considered a relatively positive outcome.
On the market front, Glenmark Pharma shares saw some volatility, falling by as much as 1.5 percent to touch a low of ₹ 1,634.55 on June 18. The stock is still around 11 percent below its 52-week high of ₹ 1,830.05, which it had touched in October 2025. However, it remains significantly above its 52-week low of ₹ 1,199.95, seen in June 2024.
The recent price trajectory shows renewed investor interest, with the stock gaining 12.5 percent in June so far, following a 5.5 percent rise in May. This follows a choppy start to the year where the stock fell over 10 percent in April, surged 20.5 percent in March, and posted losses of 12 percent and 9.7 percent in February and January respectively.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Hindu

4 hours ago

• The Hindu

Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner

Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.

News18

6 hours ago

• News18

Seeking Pole Position In Rare Earth Magnet Sector, India Plans Rs 3,500 Cr To Rs 5,000 Cr Scheme

This strategic initiative responds to China's recent decision in April 2025 to tighten export rules on rare earth materials and magnet products, disrupting global supply chains India is poised to launch a substantial scheme valued between Rs 3,500 crore and Rs 5,000 crore, aimed at significantly boosting domestic production of rare earth minerals and the essential magnets derived from them, according to reports. This strategic initiative responds to China's recent decision in April 2025 to tighten export rules on rare earth materials and magnet products, which has disrupted global supply chains. These new restrictions have caused bottlenecks in vital sectors in India, the US, and Europe, particularly affecting the automotive and technology industries that heavily depend on these specialised magnets. Despite possessing an estimated 6.9 million metric tonnes of rare earth reserves, ranking fifth globally, India has historically lacked a strong manufacturing base for rare earth magnets. Data from the fiscal year ending March 2025 underscores this dependency, with India importing 53,748 metric tonnes of these magnets, mainly from China. This heavy reliance has become a strategic vulnerability, particularly as Chinese rare earth product exports dropped by 61 per cent in May 2025 compared to the same month last year, hitting a five-year low. In addition to financial incentives, the government is considering other supportive measures, including potential tariff exemptions for machinery used in rare earth processing and magnet manufacturing. Regulatory adjustments under the Mines and Minerals (Development and Regulation) Act are also being explored to streamline the process for domestic production. This move follows a comprehensive ministerial-level assessment that highlighted the urgent need for India to secure alternative supply sources for these crucial materials. Indian automobile manufacturers, facing potential production cuts by July due to the supply crunch, have been vocal in urging the government for timely support. The long-term goal is clear: to establish India as a significant rare earth magnet manufacturing hub and reduce China's dominance in this critical segment of the global supply chain.

Hindustan Times

8 hours ago

• Hindustan Times

Get the Best Fixed Deposit Interest Rates: Tips and Tricks

Fixed deposits (FDs) have remained one of the most trusted investment tools for Indian savers across generations. Known for their simplicity, safety, and guaranteed returns, FDs offer peace of mind to investors looking for capital protection and predictable income. But not all fixed deposits offer the same returns. If you're planning to invest, knowing how to get the best FD interest rates can significantly boost your savings over time. In this guide, we'll walk you through practical tips and strategies to maximise returns—and introduce you to Bajaj Finance Fixed Deposits, which offer up to 6.95% p.a. for non-senior citizens and up to 7.30% p.a. for senior citizens. A fixed deposit is a financial instrument where you invest a lump sum for a fixed tenure at a pre-agreed interest rate. The bank or financial institution pays you interest either periodically or at maturity. With low risk and stable returns, fixed deposits are ideal for conservative investors and those saving for short- to medium-term goals. Several factors influence the rate of interest you receive on your FD: Bajaj Finance offers some of the most attractive FD rates in India—up to 7.30% p.a. for senior citizens. Open a Bajaj Finance FD and enjoy assured growth on your savings. Do not settle for the first FD offer you come across. Compare rates across: Longer-tenure FDs usually offer better rates. If you won't need the money soon, lock in for a few years to maximise returns. Bajaj Finance FDs are available for tenures between 12 and 60 months, with flexible payout options. Cumulative FDs let your interest earn interest. Ideal if you don't need periodic payouts. Instead of putting all your savings in one FD, divide them across multiple FDs with different maturities. If you're 60+, take advantage of higher interest rates specially designed for retirees. Online booking can unlock additional interest or special offers. Bajaj Finance makes it easy to: Book Your Bajaj Finance FD Online for attractive rates and a hassle-free experience. If interest rates are rising, lock in higher rates with longer a falling cycle, go for short-term FDs and wait to reinvest later. Keep an eye on RBI updates and financial news. Some institutions offer better rates on renewals. Avoid lapses and earn uninterrupted interest by enabling auto-renewal. Always review the prevailing rate before renewing. While maximising returns, don't ignore these important considerations: With smart planning and a few strategic choices, you can make your fixed deposit work harder for you. Compare rates, pick the right tenure, consider laddering, and book online for extra benefits. In today's unpredictable economic environment, a reliable fixed deposit—like the one from Bajaj Finance offering up to 7.30% p.a.—can bring stability and predictable returns to your portfolio. Start your FD with Bajaj Finance today and secure high returns with guaranteed peace of mind. Book Now. Note to readers: This article is part of HT's paid consumer connect initiative and is independently created by the brand. HT assumes no editorial responsibility for the content, including its accuracy, completeness, or any errors or omissions. Readers are advised to verify all information independently. Want to get your story featured as above? click here!